SkylineDx announced that an independent meta-analysis has confirmed the performance of its Merlin CP-GEP assay in correctly stratifying melanoma patients for sentinel lymph node biopsy (SLNB). This unbiased analysis verifies the test to enable clinicians to select patients who can safely avoid the invasive SLNB procedure, reducing unnecessary operations and their associated risks.
Health Technology Insights: Finvi Adds AI-Powered Denial Intelligence Engine to the Artiva HCx Platform
The Merlin CP-GEP test integrates clinicopathologic findings with gene expression profiling to assess the risk of metastasis to sentinel lymph nodes. With a more accurate risk prediction, the test facilitates personalized treatment decisions and enhanced patient care. The meta-analysis pooled information from numerous clinical trials, involving hundreds of patients in different clinical environments. It proved that the Merlin CP-GEP assay provides for consistent results over a period of time, making it possible to identify patients confidently. This dips overtreatment and healthcare expenditure while sustaining good standards of care. SkylineDx further has used this expertise in precision medicine.
SkylineDx continues to create new diagnostic products that enable physicians to make better-informed decisions, enhance patient outcomes, and maximize healthcare and utilizing the resources wisely. This validation further renforces the clinical utility of the Merlin CP-GEP assay and SkylineDx’s commitment to advancing cancer diagnostic innovation.
Health Technology Insights: FDA Approves Sirtex’s SIR-Spheres Y-90 for Liver Cancer Treatment
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
